CLINICAL COURSE AND OUTCOME IN CLASS IC ANTIARRHYTHMIC OVERDOSE

References

• Denkschrift D FG. Dokumentation und Information in der klinisch-toxikologischen Analytik. Verlag Chemie, Weinheim, New York 1817
   Google Scholar
• Ellenhorn M J, Barceloux D G. Medical Toxicology - Diagnosis and Treatment of Human Poisoning. Elsevier, New York 1988; 8
   Google Scholar
• Hollmann M, Brode E, Hotz D, Kaumeier S, Kehrhahn O H. Investigations on the pharmacokinetics of propafenone in man. Arzneim-Forsch/Drug Res 1983; 33: 763–770
   PubMed Web of Science ®Google Scholar
• Nappi J M, Anderson J L. Flecainide: A new prototype anti-arrhythmic agent. Pharmacotherapy 1985; 5: 209–218
   PubMed Web of Science ®Google Scholar
• Sellers T D, Di Marco J P. Sinusoidal ventricular tachycardia association with flecainide acetate. Chest 1984; 85: 647–649
   PubMed Web of Science ®Google Scholar
• Rosen D M, Woosely R L. Drug therapy. Flecainide. N Engl J Med 1986; 315: 36–41
   PubMed Web of Science ®Google Scholar
• Holmes B, Heel R C. Flecainide: A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Durgs 1985; 29: 1–33
   Google Scholar
• Plomp T A, Boom H T, Maes R AA. Measurement of flecainide plasma concentratiosn by high perfomane liquid chromatography with fluorescence detection. J Anal Toxicol 1986; 10: 102–106
   PubMed Web of Science ®Google Scholar
• Conrad G J, Ober R E. Metabolism of flecainide. Am J Cardiol 1984; 53: 41B–51B
   PubMed Web of Science ®Google Scholar
• McQuinn R L, Quarfoth G J, Johnson J D, et al. Biotransformation and elimination of 14C-flecainide acetate in humans. Drug Metabol Dispos 1984; 12: 414–420
   PubMed Web of Science ®Google Scholar
• Köppel C, Tenczer J, Eckart K, Schwarz H. Structure elucidation of flecainide metabolites in urine by GC/Ms and MS/Ms. presented at the 10th International Mass Spectrometry Confernece, Swansea, 1985
   Google Scholar
• Muhiddin K A, Turner P, Blackett A. Effect of flecainide on cardiac ouput. Clin Pharmaco Ther 1985; 37: 260–263
   PubMed Web of Science ®Google Scholar
• Späth G. Die Antiarrhythmiak Aimalin und Prajmalinbitartrat, Kardiologische Reihe 2. de Gruyter, Berlin 1983
   Google Scholar
• Köppel C, Tenczer J, Arndt I. Metabolic disposition of ajmaline. Eur J Drug Metab Pharmacokin 1989; 14: 309–316
   PubMed Web of Science ®Google Scholar
• Köppel C, Wagemann A, Martens F. Pharmacokinetics and antiarrhythmic efficacy of intravenous ajmaline in ventricular arrhythmia of acute onset. Eur J Drug Metab Pharmacokin 1989; 14: 161–164
   PubMed Web of Science ®Google Scholar
• Hausleiter H J, Achtert G, Khan M A, Kukovetz W R, Beulber E. Pharmakokinetik und Biotransformation von N-Prophy-ajmalinhydrogentartrat beim Menschen. Eur J Drug Metabol Pharmacokin 1982; 7: 329–339
   PubMedGoogle Scholar
• Siddoway L A, Thompson K A, McAllister C B, et al. Polymorphism of proparfenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987; 75: 785–791
   PubMed Web of Science ®Google Scholar
• Zekorn C, Achtert G, Hausleiter H J, Moon C H, Eichelbaum M. Pharmacokinetics of N-prophylajmalin in relation to polymorphic sparteine oxidation. Klin Wochenschr 1985; 63: 1180–1186
   PubMedGoogle Scholar
• Gross A S, Mikus G, Fischer C, Hertrampf R, Gundert-Remy U, Eichelbaum M. Stereoselective disposition of flecainide in realtion to the sparteine/debrisoquine metabolizer phenotype. Br J Clin Pharmac 1989; 28: 555–566
   PubMed Web of Science ®Google Scholar
• Riegger A JG, Dilger J, Roth W, Wiedemann K H, Lieban G. Elimination von Ajmalin durch verschiedene Entgitungsverfahren. intensivmed 1980; 17: 57–60
   Google Scholar
• Beu-Scharchar C, Kishon Y. Intoxication with ajmaline in an infant. Chest 1979; 76: 97–98
   PubMed Web of Science ®Google Scholar
• Riboulet G., Efthymiou M L, Conso F, Gariner R., Caramela P, Gaultier M. Actue intoxication by ajmaline. Vet Hum Toxicol 1979; 21: 91–92
   PubMedGoogle Scholar
• Binder C, Wimmer M. Ein Fall von Ajmalin-Intoxikation im Kleinkindesalter. Wien klin Wschr 1972; 84: 67–69
   PubMedGoogle Scholar
• Almong C, Maidan A, Pik A, Schlesinger Z. Acute intoxication with ajmaline. Israel J Med Sci 1979; 15: 570–572
   PubMedGoogle Scholar
• Hager W, Friedrich K H, Wink K, Wegehaupt R. Suizidversuch mit Ajmalin. Dtsch Med Wschr 1968; 93: 1809–1812
   PubMedGoogle Scholar
• Jornod J C, Barrelet J A. Suicidal attempt by overdosage of ajmaline. Amer Heart J 1965; 70: 719
   PubMed Web of Science ®Google Scholar
• Caramella J P, Guerot C l, Valere P E, Tricot R, Bismuth C H, Riboulet G. Toxicité cardiaque de l'ajmaline, Comparision des intoxications aigues volontaires et des accidents du test é l'ajmaline. Arch Mal Coeur 1982; 75: 613–620
   PubMedGoogle Scholar
• Weidner A, von Philipsborn G. Vergleichende experimentelle Untersuchungen über Intoxikationen mit Ajmalin und N-n-Propyl-ajmaliniumhydrogentartrat. Arzneimforsch/Drug Res 1971; 21: 685–687
   PubMedGoogle Scholar
• Böosche J, Mattern R. Tödlicher Vergiftungsfall mit dem Antiarrhythmikum Propafenon. Beitr qerichtl Med 1980; 38: 231–234
   PubMedGoogle Scholar
• Fach W A, Mai B V, Preusler W, Becker H J. Flecainid Intoxikation. Inn Med 1984; 11: 27
   Google Scholar
• Wurzberger R, Witter E, Avenhaus H, Hennemann H, Becker J U. Hämoperfusion bei Flecainidintoxikation. Klin Wochenschr 1986; 64: 442
   PubMedGoogle Scholar
• Gelbke H P, Schlicht H J. Suicide by an overdose of N-prphyl-ajmaliniunm bitartrate. Arch Toxical 1977; 37: 135–141
   PubMedGoogle Scholar
• Brettel H F, Schmid K, Koch U. Über eine rasch tödlich verlaufene Vergiftung mit Prajmaliumbitartrat. Z Rechstmed 1978; 82: 231
   PubMedGoogle Scholar
• Köppel C, Tenczer J. Identification and quantitation of durgs on an emergency basis with EI, CI and NCI gas chromatogaphy/mass spectrometry in a toxicological labortaroy. Int J Mass Spectrom Ion Phys 1983; 48: 213–216
   Web of Science ®Google Scholar
• Harper J F. peritz' F-test: basic prgoram of a robust multiple comparison test for statistical analysis of all differences among group means. Comput Biol Med 1984; 14: 437–445
   PubMed Web of Science ®Google Scholar
• Lee J T, Kroemer H K, Silberstein D J, Funck-Brentano C, et al. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med 1990; 322: 1764–1768
   PubMed Web of Science ®Google Scholar
• Nitsch J, Köhler U, Lüderitz B. Hemmung der Flecainid-resorption durch Aktivkohle. Z Kardiol 1987; 76: 289–291
   PubMedGoogle Scholar
• Pentel P R, Goldsmith S R, Salerno D M, et al. Effect of hypertonic sodium bicarbonate on encainide overdose. Am J Cardiol 1986; 57: 878–879
   PubMed Web of Science ®Google Scholar
• Keyler D E, Pentel P R. Hypertonic sodium bicarbonate partially reverses QRS prolongation due to flecainide in rats. Life Sciences 1989; 45: 1575–1580
   PubMed Web of Science ®Google Scholar
• Chouty F, Funck-Brentano C H, Leenhardt A, Aliot E, Haissaguerre M, Slama R. Intravenous sodium lactate as a treatment of class I antiarrhythmic agent overdose. Circulation 1989; 80: 430
   Google Scholar